Business Context and Reporting Period
Company: ZIMMER BIOMET HOLDINGS, INC. (ZBH)
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2025
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) to acquire Paragon 28, Inc.
Key Financial Metrics and Transaction Terms
This filing details a merger agreement rather than periodic financial results. Key financial terms include:
- Merger Consideration: $13.00 in cash per share of Paragon 28 common stock.
- Contingent Value Rights (CVRs): One CVR per share, entitling holders to up to $1.00 per CVR based on 2026 Net Revenue milestones.
- Revenue Milestones for CVRs:
- No payment if 2026 Net Revenue is below $346 million.
- Full $1.00 payment if 2026 Net Revenue reaches $361 million.
- Linear payment for revenue between $346 million and $361 million.
- Termination Fee: $40 million payable by Paragon 28 to Zimmer Biomet under specific termination scenarios (e.g., Superior Proposal).
- Financing: The transaction is not subject to a financing condition.
Note: The filing does not provide Zimmer Biomet's current revenue, profit, cash flow, or debt levels.
Material Changes and Transaction Structure
Zimmer Biomet Holdings, Inc. (via its subsidiary Zimmer, Inc.) has agreed to acquire Paragon 28, Inc. through a merger with a wholly-owned subsidiary. Key structural elements include:
- Stockholder Approval: Required from holders of a majority of Paragon 28 common stock.
- Regulatory Approvals: Subject to HSR Act waiting periods and foreign regulatory approvals.
- Equity Treatment: Outstanding Paragon 28 stock options and RSUs will vest and convert to cash (based on the $13.00 price) and CVRs. PSUs will vest assuming attainment of specified performance goals.
- Executive Retention: Paragon 28 CEO Albert DaCosta has entered a Voting Agreement to support the merger and an Offer Letter to serve as Global President, Foot and Ankle post-closing.
Guidance, Outlook, Risks, and Contingencies
Outlook and Timeline:
- Outside Date: The agreement must be consummated by November 28, 2025, extendable to January 28, 2026.
- Integration: Management anticipates realizing benefits from the merger, though no specific financial guidance was provided in this filing.
- Closing Conditions: Failure to obtain stockholder approval, regulatory clearance, or the occurrence of a Material Adverse Effect could prevent closing.
- Competing Offers: Paragon 28 retains a "fiduciary out" to negotiate a Superior Proposal, potentially triggering the $40 million termination fee.
- Operational Disruption: Risks include diversion of management attention, difficulty maintaining business relationships, and integration challenges.
- CVR Uncertainty: There is no assurance that the 2026 revenue milestones will be met to trigger CVR payments.
- Legal and Regulatory: Risks of litigation, shareholder actions, and regulatory conditions.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and CVR Agreement in the definitive proxy statement.
- Monitor the status of regulatory approvals (HSR and foreign jurisdictions).
- Review Paragon 28's historical financials to assess the achievability of the $346M–$361M 2026 Net Revenue milestone.
- Track the outcome of the Paragon 28 stockholder vote required for approval.
- Assess potential impacts on Zimmer Biomet's stock price and integration costs not detailed in this 8-K.